Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: anavex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2022 | $16.00 → $11.00 | Overweight → Neutral | Cantor Fitzgerald |
| 6/23/2022 | $40.00 | Buy | Berenberg |
| 2/2/2022 | $39.00 → $42.00 | Buy | HC Wainwright & Co. |
| 9/23/2021 | $35.00 | Buy | BTIG Research |
| 6/28/2021 | $25.00 → $39.00 | Buy | HC Wainwright & Co. |
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's d
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City. The presentation will take place on Monday, September 9, 2024,
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2024. "We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive result
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2024, on Tuesday, August 6, 2024. Management will host a conference call on Tuesday, August 6, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company's
ANAVEX®2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders Plans advancing to initiate a clinical trial in individuals with FXS NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome and Fragile X syndrome (FXS), a ma
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups Benefits of blarcamesine on both amyloid-beta and brain volume, two underlying pathological hallmarks of Alzheimer's disease EMA submission expected in Q4 NEW YORK, July 28, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopment
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024. An audio webcast will be accessible on demand beginning on Thursday,
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously
Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously
BTIG Research initiated coverage of Anavex with a rating of Buy and set a new price target of $35.00
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $39.00 from $25.00 previously
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $25.00 from $17.00 previously
Cantor Fitzgerald resumed coverage of Anavex Life Sciences with a rating of Overweight and set a new price target of $25.00 from $10.00 previously
Cantor Fitzgerald resumed coverage of Anavex Life Sciences with a rating of Overweight
Cantor Fitzgerald reiterated coverage of Anavex Life Sciences with a rating of Overweight and set a new price target of $25.00 from $10.00 previously
LADENBURG THALM/SH SH resumed coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $20.00
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
S-3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
DEF 14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
144 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2024. "We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive result
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2024, on Tuesday, August 6, 2024. Management will host a conference call on Tuesday, August 6, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company's
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2024. "We are encouraged by the very recently issued FDA guidance for Early Alzheimer's disease, which states that one cognitive measurement alone, li
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024. Management will host a conference call on Thursday, May 9, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strate
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2023. "Exciting progress in the field related to treating neurodegenerative diseases highlights the significant potential for our broad therapeutic portfolio and dif
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended December 31, 2023, on Wednesday, February 7, 2024. Management will host a conference call on Wednesday, February 7, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Compa
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2023. "We are very excited to be entering a new phase of the Company's history. For the first time we initiated the process of submitting a Marketing Authoris
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023. Management will host a conference call on Monday November 27, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy.
On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023 Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study in Alzheimer's disease with convenient oral treatment to be released in the second half of 2023 Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its quarter ended June 30, 2023, on Tuesday August 8, 2023. Management will host a conference call on Tuesday August 8, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following manage
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing c
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today announced the appointment of David Goldberger, RPh, MLS as Senior Vice President Regulatory Affairs. Mr. Goldberger brings over 40 years of pharmacy practice and pharmaceutical industry experience and has most recently been with Otsuka Pharmaceuticals Research and Development (Otsuka) as Vice President Glo
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board. Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer's and Memory Disorders Program at Barrow Neurological Institute. He is also a professor and the Vice Chair of Research in
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. Dr. Jin will draw on his extensive experience, including recently as the Statistical Team Leader at the U.S. Food and Drug Administration (FDA). Dr. Jin provided statistical review coverage and expertise for neurological
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board. Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study. Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an A
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer, effective immediately. Before joining Anavex over three years ago, Dr. Kaufmann was the Director of the Center for Translational Research a
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in
EF Hutton analyst Jason Kolbert initiates coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and announces Price Target of $46.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday. Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading following second-quarter results. CrossFirst Bankshares reported quarterly earnings of 37 cents per share, according to data from Benzinga Pro. CrossFirst Bankshares shares dipped 12.3% to $13.98 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Applied Therapeutics, Inc. (NASDAQ:APLT) fell 11.8% to $5.24 in pre-market trading after gaining 7% on Monday. Owens & Minor, Inc. (NYSE:OMI) dipped 10.6% to $12.35 in pr
Shares of Match Group, Inc. (NASDAQ:MTCH) rose sharply in today's pre-market trading. Starboard Value has taken a keen interest in Match Group. The hedge fund has accumulated a stake of over 6.5% in the online dating company and is advocating for a potential sale if the company's performance does not improve, The Wall Street Journal reported on Monday, citing people familiar with the matter. Match Group shares jumped 8% to $34.56 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Conduit Pharmaceuticals Inc. (NASDAQ:CDT) gained 89.8% to $0.4556 in pre-market trading after declining over 8% on Monday. Meiwu Technology Company Limited (NA
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $40 price target.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.5% on Monday. Shares of GSK plc (NYSE:GSK) fell sharply in today's pre-market trading after the company said it will appeal a ruling made by the Delaware State Court regarding its ongoing ranitidine litigation. GSK shares tumbled 9.2% to $40.66 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. The Boston Beer Company, Inc. (NYSE:SAM) shares fell 9.5% to $ 284.04 in pre-market trading. Boston Beer shares jumped around 22% on Friday following a report suggesting the company is in talks to sell itself to Suntory. Boston Beer later issued a state
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $40 price target.
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 176.47 percent decrease over earnings of $0.17 per share from the same period last year.
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year.
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. • Scotts Miracle Gro (NYSE:SMG) is expected to report quarterly loss at $1.53 per share on revenue of $412.83 million. • TotalEnergies (NYSE:TTE) is projected to report quarterly earnings at $2.28 per share on revenue of $41.80 billion. • Equinor (NYSE:EQNR) is likely to report earnings for its fourth quarter. • Euronet Worldwide (NASDAQ:EEFT) is estimated to report quarterly earnings at $1.76 per share on revenue of $944.71 million. • Flex LNG (NYSE:FLNG) is likely to report quarterly earnings at $0.67 per share on revenue of $9